Article
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2008
Neubauer Andreas, Maharry Kati, Mrózek Krzysztof, Thiede Christian, Marcucci Guido, Paschka Peter, Mayer Robert J, Larson Richard A, Liu Edison T, Bloomfield Clara D
Abstract excerpt
PURPOSE: RAS mutations occur in 12% to 27% of patients with acute myeloid leukemia (AML) and enhance sensitivity to cytarabine in vitro. We examined whether RAS mutations impact response to cytarabine in vivo. PATIENTS AND METHODS: One hundred eighty-five patients with AML achieving complete remission on Cancer and Leukemia Group B study 8525 and randomly assigned to one of three doses of cytarabine postremission...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.